IL-6 antisense-mediated growth inhibition in a head and neck squamous cell carcinoma cell line

In Vivo

Volumn 25, Issue 4, 2011, Pages 579-584

  Bran, Gregor ^a   Götte, Karl ^a   Riedel, Katrin ^b   Hörmann, Karl ^a   Riedel, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antisense; Head and neck squamous cell carcinoma; Interleukin 6

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 6; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GENE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

EID: 79960650416     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lingen MW: Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med 10: 153-164, 1999.
2. Mashberg A: Head and neck cancer. N Engl J Med 328: 1783-1784, 1993.
3. Hanna E, Alexiou M, Morgan J, Badley J, Maddox AM, Penagaricano J et al: Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 130: 861-867, 2004. (Pubitemid 38915974)
4. Loose D and Van de Wiele C: The immune system and cancer. Cancer Biother Radiopharm 24: 369-376, 2009.
5. Puchalski T,Prabhakar U, Jiao Q, Berns B and Davis HM: Pharmacokinetic and pharmacodynamic modelling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16: 1652-1661, 2010.
6. Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M et al: Overexpression if interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 31: 67-75, 2011.
7. Liu Q, Li G, Li R, Shen J, He Q, Deng L et al: IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 100: 165-176, 2010.
8. Wojcik E, Jakubowicz J, Skotnicki P, Sas-Korczynska B and Kulpa JK: IL-6 and VEGF in small cell lung cancer patients. Anticancer Res 30: 1773-1778, 2010.
9. Lukasewicz M, Mroczko B and Szmitkowski M: Clinical Significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 117: 247-251, 2007. (Pubitemid 47515189)
10. Gasche JA, Hoffmann J, Boland CR and Göel A: Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer [Epub ahead of print] 2010.
11. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE et al: Interleukin-6 predicts recurrence and survial amog head and neck cancer patients. Cancer 113: 750-757, 2008.
12. Riedel F, Zaiss I, Herzog D, Götte K, Naim R and Hörmann K: Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 25: 2761-2765, 2005.
13. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31, 1995.
14. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W and Hörmann K: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Oto-Rhino-Laryngol 257: 332-336, 2000. (Pubitemid 30612326)
15. Riedel F, Götte K, Bergler W and Hörmann K: Inverse correlation of angiogenic and apoptotic markers in squamous cell carcinoma of the head and neck. Oncology Reports 8: 471-476, 2001.
16. Nakashima T, Hudson JM and Clayman GL: Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck 22: 483-488, 2000. (Pubitemid 30483057)
17. Riedel F, Götte K, Schwalb J, Schäfer C and Hörmann K: Expression of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Oto-Laryngol 120: 105-111, 2000. (Pubitemid 30434141)
18. Mott JL and Gores GJ: Targeting IL-6 in cholangiocarcinoma therapy. Am J Gastroenterol 102: 2171-2172, 2007.
19. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, Bikfalvi A and Javerzat S: Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. In J Cancer 125: 1054-1064, 2009.
20. Riedel F, Götte K, Li M, Hörmann K and Grandis JR: EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 21: 11-16, 2002.
21. Sporn MB and Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878-880, 1990.
22. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I and Blay JY: IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 111: 653-661, 2004. (Pubitemid 39062886)
23. Mirabelli CK, Bennett CF, Anderson K and Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 6: 647-661, 1991.
24. Smyth AP, Rook SL, Detmar M and Robinson GS: Antisense oligonucleotides inhibit vascular endothelial growth factor/ vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol 108: 523-526, 1997. (Pubitemid 27148292)
25. Zheng SX, Zhou LJ, Zhu XZ and Jin YX: Antisense oligonucleotide inhibits vascular endothelial growth factor in human glioma cells. Acta Pharmacol Sin 21: 211-214, 2000.
26. Kanazawa T, Nishino H, Hasegawa M, OMa Y, Iino Y, Ichimura K et al: Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264: 815-821, 2007. (Pubitemid 46817497)
27. Kong B, Isozaki T and Sasaki S: IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechansim. Gynecol Oncol 63: 78-84, 1996. (Pubitemid 26337970)
28. Loeffler S, Fayard B, Weis J and Weissenberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. In J Cancer 115: 202-213, 2005. (Pubitemid 40586728)
29. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW et al: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379, 1999. (Pubitemid 29282941)
30. Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML and Lin JT: Correlation between serum levels of interleukin-6 and vascular endothelial factor in gastric carcinoma. J Gastroenterol Hepatol 17: 1165-1169, 2002.
31. Schlingensiepen KH, Jaschinski F, Lang SA, Moser C, Geissler EK, Schlitt HJ et al: TGF-β2 gene silencing with Trabedersen (AP 12009) in pancreatic cancer. Cancer Sci [Epub ahead of print] 2011.
32. Chen L, Zhu Y, Li H, Wang GL, Wu YY, Lu YX et al: Knockdown of TSPAN1 by RNA silencing and antisense technique inhibits proliferation and infiltration of human skin squamous carcinoma cells. Tumori 96: 289-295, 2010.